

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS**

JANSSEN BIOTECH, INC.)	
)	
Plaintiff,)	
)	
v.)	Civil Action No. _____
)	
CELLTRION HEALTHCARE CO., LTD., CELLTRION, INC., and HOSPIRA, INC.,)	JURY TRIAL DEMANDED
)	
Defendants.)	
_____)	

COMPLAINT

Plaintiff Janssen Biotech, Inc. (“Janssen”) for its Complaint against Defendants Celltrion Healthcare Co., Ltd. and Celltrion, Inc. (together, “Celltrion”), and Hospira, Inc. (“Hospira”) (collectively, “Defendants”) alleges as follows.

NATURE OF THE ACTION

1. This is an action for infringement of U.S. Patent No. 7,598,083 (“the 083 patent”) under 35 U.S.C. § 271(e)(2)(C)—which was enacted in 2010 in the part of the Patient Protection and Affordable Care Act known as the Biologics Price Competition and Innovation Act (“BPCIA”)—as well as 35 U.S.C. § 271(a) and (b).

2. Pursuant to the BPCIA, Celltrion and Hospira submitted an abbreviated Biologic License Application (“aBLA”) seeking permission to market a biosimilar version of Janssen’s revolutionary biological medicine Remicade® (infliximab).

3. The 083 patent includes claims that cover particular compositions of cell culture media, the important material that is used to grow the living cells that produce biologic medicines such as infliximab.

4. In an earlier-filed action (*Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd.*, No. 15-cv-10698 (D. Mass. filed Mar. 6, 2015), hereinafter “the 2015 action”), Janssen asserted claims against Celltrion and Hospira for technical acts of infringement of the 083 patent under the BPCIA. In particular, Janssen asserted claims under 35 U.S.C. § 271(e)(2)(C)(ii) for technical infringement of the 083 patent based on Celltrion’s and Hospira’s failure to provide manufacturing information as required by the BPCIA and on Janssen’s analysis of the limited information provided by Celltrion and Hospira prior to the lawsuit.

5. In another earlier-filed action (*Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd.*, No. 16-cv-11117 (D. Mass. filed June 14, 2016), hereinafter “the 2016 action”)—later consolidated with the 2015 action—Janssen asserted claims of direct and induced infringement of the 083 patent under 35 U.S.C. § 271(a) and (b) against Celltrion, and claims of induced infringement of the 083 patent under 35 U.S.C. § 271(b) against Hospira, based on information that Janssen learned in the course of pursuing the 2015 action.

6. Janssen commenced the 2015 action following Defendants’ failure to comply with the BPCIA’s pre-litigation procedures set forth in 42 U.S.C. § 262(l). Specifically, prior to the 2015 action, Defendants failed to provide Janssen with “other manufacturing information” as set forth in 42 U.S.C. § 262(l)(2)(a), making it impossible for Janssen to assess infringement of the 083 patent. Thereafter, Defendants asserted that the good-faith negotiations and subsequent procedures for identifying patents for immediate litigation, as set forth in 42 U.S.C. § 262(l)(4) and (5), were “moot” and refused to participate in them.

7. After the commencement of the 2015 action, Janssen obtained information about the cell culture media custom made by HyClone Laboratories, Inc. (“HyClone”) for Celltrion’s use in the manufacture of Defendants’ infliximab biosimilar, which is then sold by Celltrion and

Hospira. This information shows that Celltrion has caused HyClone, Celltrion's agent and supplier, to develop and manufacture in the United States (Logan, Utah) cell culture media ("Celltrion media" or "Celltrion custom-made media") that infringe claims of Janssen's 083 patent.

8. Celltrion has already used these infringing media in the manufacture of large quantities of Defendants' infliximab biosimilar that have been sold, and are currently being sold, both outside and inside the United States. Defendants' infliximab product, as manufactured using the infringing media, was approved by the FDA as a biosimilar of Janssen's Remicade® and has been sold on the U.S. market since late 2016. Celltrion controlled the development of the infringing media, directing details of its composition and instructing HyClone to use the combinations of ingredients that together infringe the claims of the 083 patent.

9. Hospira has obtained marketing approval and sold and continues to sell infliximab biosimilar, manufactured by Celltrion using the infringing media, both outside and inside the United States pursuant to marketing agreements with Celltrion.

10. Recently, the Court in the consolidated 2015 and 2016 actions ruled that Defendants failed to participate in the BPCIA's pre-litigation procedures, specifically 42 U.S.C. § 262(l)(4) and (5), prior to the 2015 action, and that as a result, the limitations on remedies set forth in 35 U.S.C. § 271(e)(6)(B) would not apply to the 2016 action or to any future-filed action.

11. After the Court's ruling, Defendants' informed Janssen that they wished to initiate the previously circumvented "good-faith negotiations" under 42 U.S.C. § 262(l)(4). Defendants asserted that it was not too late to restart the BPCIA's pre-litigation procedures, notwithstanding the fact that litigation had commenced more than two years before, that discovery in the 2015

and 2016 actions was long since closed, and that the liability phase of the 083 litigation is trial ready. They contended that Janssen must file suit within 30 days after the conclusion of the supposedly renewed pre-litigation procedures in order to avoid being exposed to the limitation on remedies of 35 U.S.C. § 271(e)(6)(B) in a future-filed lawsuit.

12. Although Janssen denies that Defendants' efforts to rekindle the statutory pre-litigation procedures long after the commencement of litigation have any legal effect whatsoever, Janssen accepts Defendants' invitation to file a new action within 30 days in order to avoid the burden of responding to any future argument by Defendants that the limitations on remedies of 35 U.S.C. § 271(e)(6)(B) apply. The infringement allegations in this complaint are essentially the same as to those of the 2015 and 2016 actions with respect to the 083 patent.

PARTIES

13. Janssen Biotech, Inc. is a company organized and existing under the laws of the Commonwealth of Pennsylvania, with a principal place of business in Horsham, Pennsylvania.

14. Upon information and belief, Celltrion Healthcare Co., Ltd. and Celltrion, Inc. are companies organized and existing under the laws of the Republic of Korea. Celltrion, Inc. is a biopharmaceutical company that specializes in research and development of antibody biosimilars and biopharmaceuticals, including cell culture media development for biosimilar antibodies. Celltrion Healthcare Co., Ltd. markets and distributes such biopharmaceutical products in the United States. Celltrion Healthcare Co., Ltd. maintains an office for U.S. business operations in Cambridge, Massachusetts.

15. Upon information and belief, Hospira, Inc. is a Delaware corporation having corporate offices and a principal place of business in Lake Forest, Illinois. Hospira, Inc. is a wholly-owned subsidiary of Pfizer, Inc.

JURISDICTION AND VENUE

16. This is an action for patent infringement under the patent laws of the United States, Title 35, United States Code. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201(a), and 2202.

17. Celltrion Healthcare Co., Ltd. maintains an office for U.S. business operations in Cambridge, Massachusetts. On information and belief, among the purposes of this office is to market and distribute, in collaboration with Celltrion, Inc., products manufactured by Celltrion, Inc.

18. Celltrion Healthcare Co., Ltd. is registered to do business in Massachusetts and has consented to be sued in Massachusetts. On information and belief, among the purposes of Celltrion Healthcare Co., Ltd.'s Massachusetts business is to market and distribute products manufactured by Celltrion, Inc.

19. Celltrion Healthcare Co., Ltd. and Celltrion, Inc. previously filed a Declaratory Judgment Complaint in this District against Janssen (*see Celltrion Healthcare Co., Ltd. and Celltrion, Inc. v. Janssen Biotech, Inc.*, No. 14-cv-11613 (D. Mass. filed Mar. 31, 2014)) involving the same products at issue here.

20. Celltrion Healthcare Co., Ltd. and Celltrion, Inc. did not contest personal jurisdiction in the 2015 action and the 2016 action.

21. This Court has personal jurisdiction over Celltrion Healthcare Co., Ltd. and Celltrion, Inc.

22. Hospira has been involved in an ongoing and continuing business relationship with Celltrion concerning their infliximab product since at least 2009. On information and

belief, Hospira has been aware during that time that Celltrion maintains its office for U.S. business operations in Massachusetts.

23. Hospira entered into exclusive and co-exclusive license, distribution, and/or marketing agreements with Celltrion covering their infliximab product.

24. Hospira is obligated, or entitled, to indemnify, defend, or participate in patent litigation brought against Celltrion related to the infliximab product. Hospira is actively collaborating with Celltrion in litigation concerning Defendants' infliximab product.

25. Hospira has collaborated with Celltrion in the submission of Defendants' aBLA and markets and distributes the biosimilar infliximab product in Massachusetts.

26. Hospira has also collaborated with Celltrion in the submission of applications for marketing approval overseas and markets and distributes the infliximab biosimilar product worldwide.

27. On information and belief, Hospira is engaged in the distribution of generic pharmaceutical products throughout the world, including in Massachusetts.

28. Hospira has voluntarily and purposely directed its activities at Massachusetts residents, including by engaging in an ongoing and continuing business relationship with Celltrion, by engaging in continuous and systematic activity in Massachusetts through its authorized distributors and a Customer Fulfillment Center in Massachusetts, and by marketing its biosimilar infliximab product in Massachusetts.

29. Hospira did not contest personal jurisdiction in the 2015 action or the 2016 action.

30. This Court has personal jurisdiction over Hospira.

31. Venue is proper in this judicial district under 28 U.S.C. §§ 1391 and/or 1400(b).

32. Defendants did not contest venue in the 2015 action and the 2016 action.

THE PATENT IN SUIT

33. Janssen owns U.S. Patent No. 7,598,083 (“the 083 patent”), which covers cell culture media for use in growing antibody-producing cells.

34. On October 6, 2009, the PTO duly and properly issued the 083 patent, entitled “Chemically Defined Media Compositions.” A true and correct copy of the 083 patent is attached as Exhibit A.

35. The cell culture media covered by the 083 patent comprise 61 ingredients at various concentration ranges and were developed through the intensive efforts of the inventors.

36. The 083 patent will expire on February 7, 2027.

REMICADE® (INFLIXIMAB)

37. Janssen is a pioneer and leader in the development of biologic drugs. Janssen’s biologic drug Remicade® was one of the first drugs of its kind sold in the United States for treatment of a chronic disease.

38. Remicade® is a monoclonal antibody that binds to and neutralizes a substance in our bodies called tumor necrosis factor alpha (“TNF α ”). TNF α is an important player in our immune systems but, if it is over-produced, it can lead to chronic disease.

39. Scientists at New York University worked with scientists at Janssen’s predecessor Centocor to develop the infliximab monoclonal antibody, also known as the “cA2” antibody.

40. Although the cA2 antibody had promising in vitro properties, given its complex structure and mechanism of operation it required extensive pre-clinical and clinical development before it could become a useful medicine for human beings.

41. From the time the infliximab antibody was first discovered, it took nearly a decade for Remicade® to be approved for sale in the United States. During that time, Centocor

conducted dozens of clinical trials and spent tens of millions of dollars, with no guarantee of success.

42. Remicade® was first approved for the U.S. market in 1998. The first indication, or use, for which Remicade® was approved was the treatment of Crohn's disease, an inflammatory bowel disease that causes inflammation of the lining of the digestive tract. Remicade® was the first biological therapy approved for Crohn's disease in the United States.

43. After Remicade® entered the market, Janssen continued to pursue extensive clinical development efforts for the drug. These efforts led to the discovery that Remicade® is safe and effective for a number of additional diseases and indications other than Crohn's disease.

44. Janssen's extensive development efforts have led to 16 FDA approvals for Remicade®, including indications for use in the treatment of Crohn's disease (1998), rheumatoid arthritis (1999), ankylosing spondylitis, a chronic inflammatory disease of the axial skeleton (2004), psoriatic arthritis (2005), and ulcerative colitis, an inflammatory bowel disease (2006). Remicade® has changed the standard of care for the treatment of these diseases.

45. In total, Janssen has sponsored more than 170 clinical trials for Remicade®. Janssen has spent hundreds of millions of dollars in research and development of the drug.

46. Remicade® had been used to treat and improve the lives of more than 2.2 million patients suffering from chronic disease.

DEFENDANTS' BIOSIMILAR PRODUCT

47. Biological medicines, or biologics, are complex biological molecules that need to be grown in living cultures rather than chemically synthesized, as are the more familiar pharmaceutical products known as chemical or small-molecule drugs. Because the biologic manufacturing process is complex and uses living organisms, the structural features of a biologic

drug can vary based on the precise manner in which the biologic is made. Unlike small-molecule drugs, moreover, biological molecules generally cannot be completely characterized.

48. Because of the differences between biological and small-molecule drugs, biological and small-molecule pharmaceutical products are approved for sale in the United States through different regulatory pathways. Whereas small-molecule drugs are approved based on the submission of a New Drug Application (“NDA”) (*see* 21 U.S.C. § 355), biological products are assessed pursuant to a Biological License Application (“BLA”) (*see* 42 U.S.C. § 262(a)).

49. The BPCIA creates an abbreviated approval pathway (beginning with an aBLA) for FDA licensure of biological products upon a determination that the biological product is “biosimilar” to a previously licensed “reference product.” 42 U.S.C. § 262(k). The BPCIA defines a “biosimilar” as a biological product that is (1) “highly similar to the reference product notwithstanding minor differences in clinically inactive components”; and (2) has “no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product.” 42 U.S.C. §§ 262(i)(2)(A), (B). The BPCIA defines a “reference product” to be a “single biological product licensed under subsection (a) against which a biological product is evaluated in an application submitted under subsection (k).” 42 U.S.C. § 262(i)(4).

50. Under the BPCIA, biosimilar applicants are permitted to make use of FDA’s prior determinations as to the safety, purity, and potency of the reference product that was already approved by FDA. In particular, a biosimilar applicant must identify a single reference product that has already been approved by FDA and submit to FDA “publicly-available information regarding the Secretary’s previous determination that the reference product is safe, pure, and potent.” 42 U.S.C. § 262(k)(2)(A)(iii)(I). Consequently, the § 262(k) pathway created by the

BPCIA allows the biosimilar applicant, taking advantage of the prior efforts and investments of the reference product's developer, to reduce the time, expense, and risks of research and development and the full complement of pre-clinical and clinical testing, and to gain licensure to commercialize its biological product in the market as a biosimilar sooner and more cheaply than it could have done had it been required to submit an original BLA, as the reference product's developer did.

51. Celltrion and Hospira submitted an Investigational New Drug ("IND") application for their proposed biosimilar to Janssen's infliximab product under section 505(i) of the Federal Food, Drug, and Cosmetic Act on October 2, 2013, and the FDA accepted the IND on November 18, 2013. The IND permitted Celltrion and Hospira to conduct studies of their proposed infliximab biosimilar for use in an application for regulatory approval in the United States.

52. Celltrion and Hospira submitted an aBLA (No. 125544) for this proposed biosimilar product on or about August 8, 2014 and the FDA accepted that application for review on or about October 7, 2014. The aBLA is an application to market Celltrion's and Hospira's proposed biosimilar infliximab product in the United States. Celltrion and Hospira received approval from the FDA on April 5, 2016 to sell biosimilar infliximab in the United States.

53. In 2009, Hospira entered into an agreement with Celltrion, pursuant to which Hospira obtained the rights to co-exclusively market biosimilar infliximab in the United States. Under the terms of the same agreement, Hospira obtained the rights to co-exclusively market biosimilar infliximab in, among other places, Europe and Canada. In 2014, the agreement was amended to grant Hospira the exclusive right to commercialize the product in certain countries, including the United States. The trade name for the infliximab product marketed by Hospira is

Inflextra. Pursuant to Celltrion's agreement with Hospira, Hospira purchases infliximab from Celltrion and sells it in the markets in which it has distribution rights.

54. Celltrion and Hospira have sold and continue to sell biosimilar infliximab in more than 30 countries worldwide.

55. For example, Celltrion's and Hospira's biosimilar infliximab products have been sold in South Korea since the fourth quarter of 2012; in Finland, Norway, Czech Republic, and Portugal since the fourth quarter of 2013; in Ireland and Poland since the first quarter of 2014; in Japan since the fourth quarter of 2014; in Austria, Belgium, Canada, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden, and the UK since the first quarter of 2015; in Venezuela since the second quarter of 2015; in Brazil since the third quarter of 2015; and in the United States since the fourth quarter of 2016.

DISCOVERY OF INFORMATION REGARDING DEFENDANTS' CELL CULTURE MEDIA

56. Janssen initiated the 2015 action as a result of Celltrion's and Hospira's failure to provide information regarding the manufacturing process for their infliximab biosimilar as required by the BPCIA. Although Defendants began to provide a copy of their aBLA pursuant to 42 U.S.C. § 262(l)(2)(A) twenty days after it was accepted for review by the FDA, Defendants failed to provide "such other information that describes the process or processes used to manufacture the biological product that is the subject of such application" pursuant to the statute. In particular, Defendants failed to provide Janssen a copy of the formula of the cell culture media used to make their biosimilar product, or any other information by which Janssen could assess infringement of the 083 patent. Subsequently, Defendants refused to participate in and sought to avoid the patent dispute resolution procedures of the BPCIA.

57. Through these efforts, Defendants for a time were able to shroud their infringement of the 083 patent by refusing to provide Janssen with information necessary to investigate and evaluate potential claims. Specifically, Celltrion and Hospira refused for months to disclose the composition of the cell culture media used to manufacture their infliximab biosimilar and the location where the media are made. Throughout Janssen's efforts to obtain this information from Celltrion and Hospira, Defendants asserted that any infringing manufacturing conduct took place outside of the United States and therefore outside the reach of U.S. patents (and, thus, that the information was irrelevant). Celltrion and Hospira also pointed to differences in the concentration of certain claimed media ingredients without revealing the composition of the media. Celltrion and Hospira refused to provide any further information outside the context of litigation and insisted that Janssen file suit for technical infringement of the 083 patent under the BPCIA.

58. After the 2015 action began, Celltrion and Hospira still refused to provide information about the composition of the cell culture media used to make their biosimilar product and where the media was made. Nonetheless, HyClone (a non-party to that action) eventually disclosed the composition of the media and that it was custom made for Celltrion in Logan, Utah.

59. Having learned their compositions, Janssen was then able to confirm that the custom-made Celltrion media infringe the 083 patent under the doctrine of equivalents, as described more fully below. Janssen could then also confirm that Celltrion and Hospira had infringed, were continuing to infringe, and would in the future infringe the 083 patent.

60. After Janssen informed Celltrion and Hospira that it intended to sue for their actual infringement of the 083 patent, Celltrion and Hospira objected to any amendment of Janssen's

existing complaint or to a separate complaint for actual infringement under 35 U.S.C. § 271(a) and (b). Despite clear case law holding that a party cannot use the production of documents under a protective order in a particular case to immunize itself from suit, Celltrion and Hospira objected to modification of the protective order and to Janssen's use of the information it learned in an amended complaint or a new suit. On May 19, 2016, the Court granted Janssen's motion to modify the protective order.

61. Through discovery efforts in the prior actions, Janssen obtained information from Celltrion illustrating that it had a direct and controlling role in the development of the infringing media, which is manufactured by HyClone in the United States. Janssen has also obtained information from Hospira demonstrating Hospira has had deep involvement in various facets of the marketing and regulatory approval of the infliximab biosimilar throughout the world, and that Hospira is liable for infringement of the 083 patent due to its joint enterprise with Celltrion and also as an inducer of Celltrion and HyClone. As a result of these discoveries, Janssen brought the 2016 action.

THE IMPORTANCE OF CELL CULTURE MEDIA

62. Biologics like Remicade® and Celltrion's and Hospira's infliximab product are made from living cells rather than synthesized chemically. In general, biological medicines are significantly larger than chemical or "small-molecule" drugs and their mechanisms of action are more complex and often incompletely understood.

63. The three-dimensional structure of biologics, as well as the pattern of sugar molecules attached to them (*i.e.*, the glycosylation pattern) are difficult or impossible to characterize fully. And, because biological medicines are made in living cells rather than synthesized from chemical components, their three-dimensional structure and glycosylation pattern is affected by the manufacturing process, including the cell culture media that is used.

64. Biological products are produced in and by genetically-modified cells. These medicine-producing cells are grown in cell culture media.

65. An appropriate cell culture media contains ingredients that allow cells to grow and produce the desired biological product. The cell culture media in which a biological product is manufactured is critical to the manufacturing process and the resulting biological product.

66. Changes in the cell culture media being used to manufacture a biological product can change the nature of the biological product, including its efficacy and safety. Accordingly, a change in the cell culture media used to manufacture an approved biological product will require significant validation before being acceptable to regulatory authorities.

JANSSEN'S DEVELOPMENT OF THE 083 PATENT AND WORK WITH HYCLONE

67. Through expensive and painstaking efforts, the inventors of the 083 patent, who were employees of Centocor (Janssen's predecessor), developed a novel cell culture media formulation that could sustain high levels of cell growth and promote the production by those cells of high levels of the active ingredient in biological medicine. The formulation, reflected in Janssen's 083 patent, calls for 52 required ingredients and 9 optional ingredients.

68. Beginning in 2003, Centocor retained HyClone to manufacture this new cell culture medium on a large scale for testing for biopharmaceutical production. HyClone, which is now an indirect subsidiary of General Electric Company, is based in Logan, Utah.

69. Centocor's work with HyClone began before the October 29, 2004 priority application for the 083 patent and was subject to an April 2003 confidentiality agreement between the two companies. Under the protection of that agreement, in December 2003, Centocor gave HyClone Centocor's confidential formulation for a cell culture medium later claimed in the 083 patent.

70. HyClone was informed that the 083 media, manufactured according to the recipe Centocor provided to HyClone, worked well for large scale biopharmaceutical production. HyClone congratulated Centocor on Centocor's successful design of the 083 media.

71. HyClone sought to be Centocor's manufacturer for the 083 media. HyClone also sought to become Centocor's supplier for the media already approved to manufacture Remicade®. However, Centocor decided not to use HyClone as its supplier for cell culture media for Remicade®. HyClone is now Celltrion's supplier for cell culture media for Celltrion's and Hospira's biosimilar version of Remicade®.

DEVELOPMENT OF CELLTRION'S INFRINGING MEDIA

72. In late 2003, Celltrion and HyClone began working together in the development of cell culture media to be used to manufacture Celltrion's products. Celltrion and HyClone entered into a non-disclosure and confidentiality agreement on December 3, 2003 and since that date have entered into a variety of supply agreements for the production and sale to Celltrion of media custom-made for Celltrion for manufacturing infliximab.

73. Celltrion's first confidentiality agreement with HyClone was executed a number of months after Centocor had retained HyClone, and less than one month before Centocor provided HyClone the formulation of the 083 media under a confidentiality agreement, as discussed above. At least four of the same HyClone employees that worked on the cell culture media project for Centocor also worked on the development of Celltrion's cell culture media. HyClone did not disclose to Centocor that it was collaborating with Celltrion or that its employees who worked on Centocor's media were helping to develop media for Celltrion.

74. As described below, at least two of the cell culture media custom made by HyClone for Celltrion ("Celltrion Growth Media," or "CGM," and "Celltrion Production

Media,” or “CPM”) infringe the 083 patent. Both media are used in the production of Defendants’ biosimilar product. These cell culture media infringe claims 1-2 of the 083 patent under the doctrine of equivalents.

75. Celltrion directed HyClone’s development of custom-made cell culture media for the specific purpose of manufacturing a biosimilar version of Remicade®. Although Celltrion lacked the facilities to manufacture media on a large scale, its personnel had years of experience in the development and optimization of cell culture media for antibody production. Relying on that expertise, Celltrion exercised control over the formulation of the media, instructing HyClone on what combinations of ingredients to use and in what concentrations. Celltrion also tested antibodies made using the cell culture media to ensure that it resulted in a biosimilar product.

76. Throughout the process of developing the media for manufacture of its biosimilar infliximab, Celltrion’s scientists analyzed and tested various iterations of media provided by HyClone and instructed HyClone to make specific adjustments to the media. Sometimes Celltrion instructed HyClone to add ingredients, sometimes to remove them, and sometimes to change their concentration. At every step of the way, HyClone followed Celltrion’s instructions. HyClone also provided Celltrion with whatever information about the media formulations Celltrion needed to make specific adjustments.

77. HyClone and Celltrion thus understood that the custom-made media project was being conducted for Celltrion and under Celltrion’s control. HyClone consistently sought approval from Celltrion for various versions of the media it produced on behalf of Celltrion because the media had to meet Celltrion’s specifications.

78. Celltrion instructed HyClone to combine the ingredients that resulted in the infringing media at issue here. HyClone followed those instructions. By no later than December

2013, Celltrion, including its top executives, knew the precise formulations of the infringing media, which Celltrion has used and continues to use to manufacture infliximab sold throughout the world.

79. The development and optimization of the media was supervised by Celltrion. And because any change in the media could cause a change in the characteristics of the biosimilar product itself, Celltrion needed control over the compositions in case HyClone ever became unable to manufacture the media.

80. Celltrion and HyClone have had and continue to have a contractual relationship relating to the production of the infringing custom-made cell culture media for Celltrion. Pursuant to that relationship, the development and manufacture of media for Celltrion have been subject to Celltrion's control.

81. Since as early as 2010, HyClone has produced infringing custom-made cell culture media in Logan, Utah for use in the manufacture of Celltrion's and Hospira's infliximab product, and continues to do so.

82. Since as early as 2012, Celltrion and Hospira have sold, now in over 30 countries worldwide, biosimilar infliximab made using the infringing custom-made cell culture media. Thus, Celltrion and Hospira have profited and continue to profit from their infringement of the 083 patent in the United States.

83. The infringing custom-made cell culture media made in the United States are critical to Celltrion's and Hospira's infliximab product. The biosimilar infliximab product approved in the United States and worldwide is made using the infringing media custom-made for Celltrion (and therefore Hospira) in the United States. By ordering infliximab from Celltrion

(the manufacturer of the antibody) for its worldwide sales, Hospira also causes infringement by Celltrion and HyClone of the 083 patent.

84. Celltrion and Hospira are able to sell their approved infliximab product as a result of Celltrion's direct infringement of the 083 patent (and therefore Hospira's) and Celltrion's and Hospira's inducing the infringement of the 083 patent.

DEFENDANTS' INFRINGEMENT OF THE 083 PATENT

85. Claim 1 of the 083 patent claims "[a] soluble composition, suitable for producing a final volume of cell culture media, wherein the composition comprises the following components in the following amounts per liter of the final volume of cell culture media," followed by a list of 61 components, each with its own concentration range. For 9 of the listed components, the lower bound of the claimed concentration range is zero mg/L.

86. The cell culture media custom made for Celltrion by HyClone include all of the ingredients required by claim 1 of the 083 patent, in precisely the same chemical forms as claimed. Most of the ingredients are present in Celltrion's cell culture media in concentrations that are literally within the claimed ranges. The rest are present in Celltrion's media in concentrations that are not substantially outside of the claimed ranges.

87. The ingredients in the Celltrion media at these concentrations are insubstantially different from, and thus equivalent to, the ingredients at the claimed concentrations. Specifically, the ingredients at the concentrations in the custom media perform substantially the same function, in substantially the same way, with substantially the same results, as the ingredients at the claimed concentrations. This has been confirmed by testing performed by experts retained by Janssen prior to filing this complaint.


88. Janssen's experts performed a series of experiments to determine, on an ingredient-by-ingredient basis, what effect the literal differences from the claimed concentrations have on the performance of the Celltrion media in cell culture. Janssen's experts did this by culturing the cell line used in the examples of the 083 patent (C743B) in a series of cell culture media that the experts prepared. One of the tested media was a reproduction of Celltrion's media ("Celltrion Growth Media" in one experiment, and "Celltrion Production Media" in another). The other test media were variants of the Celltrion media, each one modified so that one of the elements (whose concentration in Celltrion's media was outside the claimed range) literally fell within the range identified in claim 1 of the 083 patent. Janssen's experts also prepared a test medium in which the concentrations of all ingredients whose concentration in Celltrion's media was outside the claimed range were modified to fall within the claimed range. Finally, Janssen's experts prepared two negative control media for each experiment. One negative control contained only phosphate buffered saline ("PBS"), a medium devoid of nutrients necessary for the cells' survival and growth. The second negative control was 80% PBS and 20% CGM or CPM. In other words, the second negative control contained all of the nutrients provided by Celltrion's media but at about one-fifth the concentration.

89. Over the course of a culture, Janssen's experts measured the concentration of living cells in the culture (the viable cell density, or "VCD"), the proportion of those cells that remained alive (the viability), and the amount of antibody produced by the cells (the titer). Each test condition was run in triplicate, and the results averaged.

90. The results of the experiments demonstrated that, with respect to each ingredient whose concentration in Celltrion's media was outside the claimed range, on an element by element basis, the difference had no substantial effect on the performance of the media in cell


culture. Nor did the all of the concentration differences together have any substantial effect on the performance of the media in cell culture.

91. The figure below shows, for each of the tested media in the CGM experiment, the viable cell density (in millions of cells per mL) of the culture as a function of the number of days of the culture. This is a measure of the ability of the tested media to promote cell growth. As is evident from the graph, all of the tested media (except for the negative controls, represented by the two lines at the bottom) exhibited substantially similar performance in this regard. (Identifying information is omitted from the graphs to protect the confidentiality of Celltrion's formula.)




92. The figure below shows, for each of the tested media in the CGM experiment, the proportion of viable (living) cells (expressed as a percentage of all cells) in the culture as a function of the number of days of the culture. This is a measure of the ability of the tested media to sustain cell life. As is evident from the graph, all of the tested media (except for the negative

controls, again represented by the two lines at the bottom) exhibited substantially similar performance in this regard.



93. Finally, the figure below shows, for each of the tested media in the CGM experiment, the titer (i.e., amount of antibody produced in culture, measured in mg/L) as a function of the number of days of the culture. This is a measure of the ability of the tested media to support the cells' production of antibody. As is evident from the graph, all of the tested media (except for the negative controls, again represented by the two lines at the bottom) exhibited substantially similar performance in this regard.



94. The results of the CPM experiment were similar to those of the CGM experiment.

95. The substantially similar performance of the tested media in the experiments confirms that the differences in concentrations of the ingredients in Celltrion’s media are insubstantial, and do not yield substantially different results in terms of cell culture.

96. Celltrion’s media also meet all the additional claim limitations of claim 2 of the 083 patent, including a buffering molecule with a pKa between 5.9 and 7.8 and a cell protectant.

97. Thus, the critically important cell culture media that Celltrion has HyClone custom-make in the United States to support its and Hospira’s sales of biosimilar infliximab products worldwide meet all of the claim limitations of claims 1-2 of the 083 patent. All the ingredients are present literally and so are the concentrations for most of them. For the remaining ingredients, the concentration limitations are met under the doctrine of equivalents. The further claim limitations of claim 2 are all literally met.

DEFENDANTS' AWARENESS OF THE 083 PATENT AND OF THEIR INFRINGEMENT

98. In December 2014, after reviewing Defendants' aBLA, Janssen sent Celltrion and Hospira a list of patents pursuant to 42 U.S.C. § 262(l)(3)(A), including the 083 patent, for which a claim of patent infringement could reasonably be asserted by Janssen based on the information contained in the aBLA.

99. Thus, at least as of December 2014, Celltrion and Hospira were aware of the 083 patent.

100. Janssen (then Centocor) gave HyClone a copy of the formulation for an embodiment of the claims of the 083 patent under a confidentiality agreement in 2004. Individuals at HyClone with access to Centocor's formulation worked on the development of Celltrion's cell culture media.

101. The application leading to the 083 patent was published on or about May 4, 2006. Subsequent to that date, anyone searching for information about Janssen's predecessor Centocor and cell culture media would have been able to locate the application and learn the composition of the claimed cell culture media.

102. Upon information and belief, Celltrion and Hospira knew or should have known that the custom-made Celltrion media infringe the 083 patent.

103. At all times relevant to this complaint, Hospira has been aware that cell culture media are crucial in the manufacture of biologic medicines. It was also aware that a change in the media used to manufacture a biologic may change the characteristics of the biologic itself, and for that reason it would be impracticable for Celltrion to change the media used to manufacture its biosimilar infliximab after obtaining regulatory approval for the product manufactured using the infringing media.

104. Therefore, upon information and belief, Hospira knows that ordering infliximab from Celltrion causes the infringement by Celltrion and HyClone of the claims of the 083 patent. Upon information and belief, Hospira has ordered infliximab from Celltrion since learning that the custom-made HyClone media infringe the 083 patent.

**DEFENDANTS' PURPORTED RENEWAL OF
THE BPCIA'S PRE-LITIGATION PROCEDURES**

105. On March 3, 2017, the Court issued a ruling in the consolidated 2015 and 2016 actions that Defendants did not engage in good-faith negotiations or the dispute resolution provisions of 42 U.S.C. § 262(l)(4) and (5) of the BPCIA prior to the commencement of the 2015 action. The Court held that the six patents that were originally the subject of the 2015 action (including the 083 patent) did not emerge “from a properly completed statutory process” and therefore would not be subject to the limitations on remedies of 35 U.S.C. § 271(e)(6)(B) in any future-filed action.

106. In light of that ruling, and with specific reference to it, Defendants sent a letter to Janssen on April 7, 2017 purporting to commence the “good-faith negotiations” required by the BPCIA. Although they registered their disagreement with the Court’s holding, Defendants wrote that “particularly given the Court’s statement that the parties have not ‘engaged in the good-faith negotiations’ . . . we are sending this letter to negotiate and to thus avoid any doubt over whether negotiations under paragraph (l)(4)(A) have occurred.” The letter stated that Defendants believed it would be appropriate to continue litigating U.S. Patent No. 6,284,471 (the 471 patent) and the 083 patent. The 471 patent has been held invalid by the Court in the 2015 action. It was also found to be unpatentable by the U.S. Patent and Trademark Office. Janssen has appealed those decisions and those appeals are still pending.

107. On April 20, 2017, Janssen responded to Defendants' letter, explaining that it was not possible to conduct the statutory good-faith negotiations after litigation had been commenced and that any attempt to do so would be legally ineffective.

108. In a April 26, 2017 letter, Defendants asserted that in light of Janssen's letter, they would consider the 15-day period for good-faith negotiations under 42 U.S.C. 262(l)(4)(B) to have expired without agreement, and would "begin the procedures described in § 262(l)(5)." Defendants then identified, pursuant to section 262(l)(5)(A), the number of patents on the patent list that they believe should be the subject of immediate litigation under the BPCIA: two (namely the 471 and 083 patents). Specifically quoting 42 U.S.C. § 262(l)(5)(B), Defendants proposed to simultaneously exchange patent lists within the next five days, *i.e.*, no later than May 1, 2017.

109. On May 1, 2017, Defendants wrote another letter to Janssen explaining that Defendants "have sought to conduct good-faith negotiations through our recent correspondence." Defendants stated that they were "proceeding to the steps set forth in the BPCIA at 42 U.S.C. § 262(l)(5)." Specifically, Defendants stated, "pursuant to 42 U.S.C. § 262(l)(5)(B)(i)(I), that the patents on the 'list of patents that [Celltrion] believes should be the subject of an action for patent infringement under paragraph (6)' are" the 471 and 083 patents. Defendants therefore asserted that, "pursuant to 42 U.S.C. § 262(l)(6)(B), if Janssen has not brought a legally valid 'action for patent infringement with respect to' the '083 patent on or before May 31, 2017 (30 days from today), under 35 U.S.C. § 271(e)(6), the 'sole and exclusive remedy that may be granted' with respect to the '083 patent, in the event it is found to be valid and infringed, 'shall be a reasonable royalty.'"

110. Janssen is filing the instant lawsuit as a direct consequence of Defendants' correspondence, in order to avoid the burden of responding to a future argument by Defendants that the limitations on remedies of 35 U.S.C. § 271(e)(6) would apply to a later-filed lawsuit.

COUNT 1

(Infringement of the 083 Patent by Celltrion Under 35 U.S.C. § 271(a))

111. Janssen incorporates by reference paragraphs 1-110 as if fully set forth herein.

112. At Celltrion's direction and control, and acting as Celltrion's agent, HyClone developed custom-made cell culture media in the United States that infringe claims 1-2 of the 083 patent under the doctrine of equivalents.

113. Under contract with Celltrion, HyClone has manufactured and continues to manufacture the infringing custom-made media in the United States for Celltrion's use in the manufacture and sale of a biological product that has been and continues to be sold by Celltrion and Hospira inside and outside of the United States under the trade names Remsima and Inflectra.

114. By directing and controlling its agent HyClone's development of the infringing media, and by participating in a contractual relationship pursuant to which HyClone continues to manufacture the infringing media, Celltrion has directly infringed and continues to directly infringe the 083 patent under 35 U.S.C. § 271(a).

115. Celltrion had actual knowledge, or was willfully blind to the fact that, Celltrion's custom-made media infringe claims 1-2 of the 083 patent.

116. Upon information and belief, Celltrion's past and current infringement of the claims of the 083 patent were and are intentional, willful, and knowing, and/or objectively or subjectively reckless. Celltrion's wrongful conduct makes this case exceptional and entitles Janssen to attorneys' fees and increased damages.

117. Celltrion's conduct has harmed and continues to harm Janssen, including by preventing it from enjoying the exclusive rights granted by the 083 patent; by causing Janssen to lose market share for and profits from Remicade® in the markets in which Defendants' biosimilar product is marketed; and by causing Janssen's licensee for the distribution of Remicade® to lose market share for and profits from Remicade® in markets in which Defendants' biosimilar product is marketed.

118. Unless Celltrion is enjoined from infringing the 083 patent, Janssen will continue to suffer irreparable loss, injury, and damages.

COUNT 2

(Infringement of the 083 Patent by Celltrion Under 35 U.S.C. § 271(b))

119. Janssen incorporates by reference paragraphs 1-118 as if fully set forth herein.

120. Using infringing custom-made cell culture media made in the United States by HyClone, Celltrion has manufactured a product that has been and continues to be sold by Celltrion and Hospira both inside and outside of the United States under the trade names Remsima and Inflectra.

121. Celltrion had actual knowledge, or was willfully blind to the fact that, Celltrion's custom-made media infringe claims 1-2 of the 083 patent.

122. By ordering the infringing custom-made cell culture media – in order to make and sell Defendants' biosimilar infliximab products – Celltrion has induced and continues to induce the infringement of claims 1-2 of the 083 patent by HyClone, under the doctrine of equivalents, under 35 U.S.C. § 271(b).

123. Upon information and belief, Celltrion's past and current inducement of the infringement of the claims of the 083 patent by HyClone was and is intentional, willful, and

knowing, and/or objectively or subjectively reckless. Celltrion's wrongful conduct makes this case exceptional and entitles Janssen to attorneys' fees and increased damages.

124. Celltrion's conduct has harmed and continues to harm Janssen, including by preventing it from enjoying the exclusive rights granted by the 083 patent; by causing Janssen to lose market share for and profits from Remicade® in the markets in which Defendants' biosimilar product is marketed; and by causing Janssen's licensee for the distribution of Remicade® to lose market share for and profits from Remicade® in markets in which Defendants' biosimilar product is marketed.

125. Unless Celltrion is enjoined from inducing HyClone's infringement of the 083 patent, Janssen will continue to suffer irreparable loss, injury, and damage.

COUNT 3
(Infringement of the 083 Patent by Hospira Under 35 U.S.C. § 271(a))

126. Janssen incorporates by reference paragraphs 1-125 as if fully set forth herein.

127. Celltrion and HyClone, under Celltrion's direction and control, have developed custom-made cell culture media in the United States that infringe claims 1-2 of the 083 patent under the doctrine of equivalents. HyClone continues to manufacture the infringing custom-made media in the United States.

128. As reflected in Hospira's agreements with Celltrion, Hospira and Celltrion have a common purpose; they have a common pecuniary interest in that purpose; and they have an equal right in and control over the direction of the enterprise. As such, Hospira and Celltrion are engaged in a joint enterprise and Hospira is jointly liable for Celltrion's actual infringement and inducement of infringement of the 083 patent as alleged above.

129. Upon information and belief, Hospira's past and current infringement of the claims of the 083 patent through its joint enterprise with Celltrion was and is intentional, willful,

and knowing, and/or objectively or subjectively reckless. Hospira's wrongful conduct makes this case exceptional and entitles Janssen to attorneys' fees and increased damages.

130. Hospira's conduct has harmed and continues to harm Janssen, including by preventing it from enjoying the exclusive rights granted by the 083 patent; by causing Janssen to lose market share for and profits from Remicade® in the markets in which Defendants' biosimilar product is marketed; and by causing Janssen's licensee for the distribution of Remicade® to lose market share for and profits from Remicade® in markets in which Defendants' biosimilar product is marketed.

131. Unless Hospira is enjoined from infringing the 083 patent, Janssen will continue to suffer irreparable loss, injury, and damage.

COUNT 4
(Infringement of the 083 Patent by Hospira Under 35 U.S.C. § 271(b))

132. Janssen incorporates by reference paragraphs 1-131 as if fully set forth herein.

133. Celltrion and HyClone, under Celltrion's direction and control, have developed custom-made cell culture media in the United States that infringe claims 1-2 of the 083 patent under the doctrine of equivalents. HyClone continues to manufacture the infringing custom-made media in the United States.

134. Hospira had actual knowledge, or was willfully blind to the fact that, Celltrion's custom-made media infringe claims 1-2 of the 083 patent.

135. Hospira actively induced the infringement by Celltrion and HyClone of the 083 patent under 35 U.S.C. § 271(b) by entering into one or more agreements with Celltrion to market and distribute a biological product made using infringing media. Hospira has ordered

and sold its infliximab products outside of the United States, knowing that infringing media is made in the United States in order to make infliximab products.

136. By continuing to sell infliximab products pursuant to its agreements with Celltrion, Hospira continues to actively induce infringement of the 083 patent by Celltrion and HyClone.

137. In addition, Hospira is jointly liable for Celltrion's active inducement of infringement of the 083 patent because, as alleged above, it is engaged with Celltrion in a joint enterprise.

138. Upon information and belief, Hospira's past and current inducement of infringement of the claims of the 083 patent by Celltrion and HyClone was and is intentional, willful, and knowing, and/or objectively or subjectively reckless. Hospira's wrongful conduct makes this case exceptional and entitles Janssen to attorneys' fees and increased damages.

139. Hospira's conduct has harmed and continues to harm Janssen, including by preventing it from enjoying the exclusive rights granted by the 083 patent; by causing Janssen to lose market share for and profits from Remicade® in the markets in which Defendants' biosimilar product is marketed; and by causing Janssen's licensee for the distribution of Remicade® to lose market share for and profits from Remicade® in markets in which Defendants' biosimilar product is marketed.

140. Unless Hospira is enjoined from inducing HyClone's and Celltrion's infringement of the 083 patent, Janssen will continue to suffer irreparable loss, injury, and damage.

COUNT 5
(Infringement of the 083 Patent by Celltrion and Hospira
Under 35 U.S.C. § 271(e)(2)(C))

141. Janssen incorporates by reference paragraphs 1-140 as if fully set forth herein.

142. Defendants failed to provide the manufacturing information set forth in 42 U.S.C. § 262(l)(2)(A) within the time period required by that statute. Defendants' failure to provide the necessary information prevented Janssen from properly assessing infringement of the 083 patent before filing the 2015 action.

143. Pursuant to 42 U.S.C. § 262(l)(3)(A)(i), the 083 patent could be, and was, included on the list of patents for which a claim of infringement could reasonably be asserted based on the making, using, offering to sell, selling, or importing into the United States of Defendants' biosimilar infliximab product.

144. Defendants' submission of their aBLA was an act of infringement of the 083 patent under 35 U.S.C. § 271(e)(2)(C)(ii), literally or under the doctrine of equivalents.

145. Alternatively, Defendants' submission of their aBLA was an act of infringement of the 083 patent under 35 U.S.C. § 271(e)(2)(C)(i), literally or under the doctrine of equivalents.

146. Unless Defendants are enjoined from infringing the 083 patent, Janssen will suffer irreparable loss, injury, and damage.

147. Upon information and belief, Defendants' infringement of the 083 patent is intentional, willful, and knowing, and/or objectively or subjectively reckless, and would make this case exceptional and entitle Janssen to attorneys' fees and increased damages.

PRAYER FOR RELIEF

WHEREFORE, Janssen respectfully requests that this Court enter judgment in its favor against Defendants and grant the following relief:

(a) a judgment that Defendants have infringed and continue to infringe the 083 patent under 35 U.S.C. § 271(a) and (b);

(b) a judgment that Defendants have infringed the 083 patent under 35 U.S.C. § 271(e)(2)(C);

(c) preliminary and/or permanent equitable relief, including but not limited to a preliminary and/or permanent injunction that enjoins Defendants, their officers, partners, agents, servants, employees, parents, subsidiaries, divisions, affiliate corporations, other related business entities and all other persons acting in concert, participation, or in privity with them and/or their successors or assigns, from making, using, importing, offering for sale or selling the Celltrion custom-made media and/or a biosimilar product made with the infringing media; and from otherwise infringing the 083 patent;

(d) damages caused by the infringement of the 083 patent, with interest and trebled, pursuant to 35 U.S.C. § 284;

(e) a declaration that this is an exceptional case and an award to Janssen of its attorneys' fees, costs and expenses pursuant to 35 U.S.C. § 285; and

(f) such other relief as this Court may deem just and proper.

DEMAND FOR JURY TRIAL

Pursuant to Rule 38(b) of the Federal Rules of Civil Procedure, Janssen demands a jury trial as to all issues triable by a jury.

Dated: May 31, 2017

/s/ Heather B. Repicky
Heather B. Repicky (BBO # 663347)
hrepicky@nutter.com
NUTTER McCLENNEN & FISH LLP
Seaport West
155 Seaport Boulevard
Boston, MA 02210
617-439-2000
FAX: 617-310-9192

Gregory L. Diskant (to be admitted pro hac vice)
gldiskant@pbwt.com
Irena Royzman (to be admitted pro hac vice)
iroyman@pbwt.com
Aron Fischer (to be admitted pro hac vice)
afischer@pbwt.com
Andrew D. Cohen (to be admitted pro hac vice)
acohen@pbwt.com
PATTERSON BELKNAP WEBB & TYLER LLP
1133 Avenue of the Americas
New York, NY 10036-6710
212-336-2000
FAX: 212-336-2222

Dianne B. Elderkin (to be admitted pro hac vice)
delderkin@akingump.com
Barbara L. Mullin (to be admitted pro hac vice)
bmullin@akingump.com
Angela Verrecchio (to be admitted pro hac vice)
averrecchio@akingump.com
Jason Weil (to be admitted pro hac vice)
jweil@akingump.com
AKIN GUMP STRAUSS HAUER & FELD LLP
Two Commerce Square
2001 Market Street, Suite 4100
Philadelphia, PA 19103-7013
215-965-1200
Fax: 215-965-1210

Attorneys for Plaintiffs